Medtronic beats second-quarter estimates on strength in heart devices segment
Medical device maker Medtronic topped Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its heart disease and diabetes devices.
Stay Ahead of the Game With Medtronic (MDT) Q2 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2025.
MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth
Medtronic's Q2 results may see a lift from solid Cardiovascular momentum and strong Diabetes segment growth.
Medtronic: Possible Earnings Beat Incoming But Still Overvalued
Medtronic plc offers stable dividends and consistent cash flow, but growth remains lackluster with revenues plateauing and limited expansion prospects. MDT's product pipeline, especially in cardiovascular health and diabetes, shows promise but is unlikely to significantly accelerate overall revenue or EPS growth. Shares are not attractively valued for growth investors, with a low risk profile but only modest returns; a 30% price drop would improve risk-reward.
Medtronic (MDT) Laps the Stock Market: Here's Why
Medtronic (MDT) closed the most recent trading day at $92.2, moving +2.38% from the previous trading session.
Medtronic: A Revitalized Dividend Aristocrat To Buy Now
Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opportunity in the underpenetrated urge urinary incontinence market. Medtronic possesses an A S&P credit rating with a stable outlook.
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Medtronic (MDT) stood at $94.21, denoting a -1.76% move from the preceding trading day.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Medtronic (MDT) settling at $95.34, representing a -1.24% change from its previous close.
Medtronic Stock's $50 Billion Gift To Investors
In the last decade, Medtronic (MDT) stock has returned a notable $52 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let's look at some numbers and compare how this payout power stacks up against the market's biggest capital-return machines.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
Medtronic (MDT) concluded the recent trading session at $96.5, signifying a -1.4% move from its prior day's close.
Medtronic plc - Special Call
Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Shagun Singh Chadha - RBC Capital Markets, Research Division Michael Polark - Wolfe Research, LLC Danielle Antalffy Presentation Ryan Weispfenning VP & Head of Investor Relations Okay. Hello, everyone.
The Rotation To Value Is On – 5 October Surprise High-Yield Picks
An “October Surprise” is usually a significant, late-breaking news event that generally occurs just before a November election and has the potential to influence its outcome.
